Results 51 to 60 of about 342 (145)

Table_1_Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.docx

, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692), Xiaojing Kang (3931046), Maoli Dan (12459273), Qian Wang (32718), Yongzhen Hong (12459282), Junqin Liang (12459270), Yingbing Sang (12459276), Kailibinuer Abulikemu (12459279)   +7 more
core   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Itch is the most burdensome symptom in atopic dermatitis (AD) and prurigo nodularis (PN) and is associated with significant psychological distress, sleep deprivation and impaired quality of life.
Kwatra, Shawn G, Jabbar-Lopez, Zarif K, Piketty, Christophe, Chen, Xiaoxiao, Ständer, Sonja, Elmariah, Sarina B, Pink, Andrew E, Yosipovitch, Gil, Cheong, Soo Yeon, Ulianov, Liliana, Silverberg, Jonathan I   +10 more
core   +1 more source

Table_3_Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.docx

, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692), Xiaojing Kang (3931046), Maoli Dan (12459273), Qian Wang (32718), Yongzhen Hong (12459282), Junqin Liang (12459270), Yingbing Sang (12459276), Kailibinuer Abulikemu (12459279)   +7 more
core   +1 more source

Beyond Histamine: Mast Cell‐Neuron Communication in Chronic Pruritic and Pain Disorders

Experimental Dermatology, Volume 35, Issue 8, August 2026.
ABSTRACT Chronic pruritic and cutaneous pain disorders are increasingly recognized as neuroimmune conditions driven by dynamic interactions between immune and sensory systems. While histamine has historically dominated models of mast cell‐mediated itch, accumulating evidence indicates that non‐histaminergic pathways are central to chronic disease.
Tomer Kagan, Gil Yosipovitch
wiley   +1 more source

Image_3_Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.tif

, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692), Xiaojing Kang (3931046), Maoli Dan (12459273), Qian Wang (32718), Yongzhen Hong (12459282), Junqin Liang (12459270), Yingbing Sang (12459276), Kailibinuer Abulikemu (12459279)   +7 more
core   +1 more source

Divergent Paths: A Comprehensive Review of Mechanisms and Clinical Implications in Atopic Dermatitis and Psoriasis

Allergy, Volume 81, Issue 7, Page 2309-2324, July 2026.
ABSTRACT Atopic dermatitis and psoriasis are two common cutaneous chronic inflammatory diseases. Although they share similar immunological mechanisms, their clinical implications in the patient are different. This review compares both diseases from different points of view such as genetics, natural history, triggers of disease, and skin barrier defects
Tali Czarnowicki, Kazunari Sugita, Zenas Yiu, Sandra Díez‐Ribas, Irene Garcia‐Jimenez, Emma Guttman‐Yassky, Luis F. Santamaria‐Babí   +6 more
wiley   +1 more source

Nemolizumab for Pruritus Control in Cutaneous T‐Cell Lymphoma: A Case Series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela, Ralf Gutzmer, Rudolf Stadler   +2 more
wiley   +1 more source

Table_2_Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.docx

, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692), Xiaojing Kang (3931046), Maoli Dan (12459273), Qian Wang (32718), Yongzhen Hong (12459282), Junqin Liang (12459270), Yingbing Sang (12459276), Kailibinuer Abulikemu (12459279)   +7 more
core   +1 more source

The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigo

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1185-1194, July 2026.
The SWITCH project assessed patients' most distressing symptoms and therapy goals, followed by an expert‐based consensus procedure to define T2T criteria for patients with chronic prurigo (CPG)/prurigo nodularis. Based on these validated criteria, a 4‐step SWITCH algorithm was established to enhance CPG therapy outcomes and reduce patient burden ...
Lea S. Stahl, Claudia Zeidler, Joyce Loewenthal, Svenja Royeck, Matthias Augustin, Robert Bissonnette, Sarina Elmariah, Brian S. Kim, Laurent Misery, Hiroyuki Murota, Hong Liang Tey, Elke Weisshaar, Gil Yosipovitch, Franz J. Legat, Adam Reich, Martin Metz, Sonja Ständer   +16 more
wiley   +1 more source